All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
B cell maturation antigen (BCMA) targeted CAR T-cell therapies has shown prominent anti-MM activity in both preclinical and clinical trials. On 27 March 2019, at the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, in Frankfurt, Germany, Yongxian Hu, from the Bone Marrow Transplantation Centre, The First Affiliated Hospital, Hangzhou, China, presented results of a recent BCMA CAR T trial in relapsed or refractory patients. The trial (ChiCTR1800017404) examined the long-term persistence of a BCMA CAR T-cell product created by lentiviral vector-mediated transduction of activated T cells. These activated T cells express a second-generation CAR with the co-stimulatory receptor 4-1BB for increased efficacy, proliferative capacity, and persistence. Objectives of the trial included the evaluation of toxicity and efficacy.
Table 1: AEs commonly affecting patients (>20% affected)
Adverse effect |
Patients affected |
---|---|
Fever |
17 |
Hypoxia |
10 |
Pancytopenia |
9 |
Chills |
7 |
Cough |
6 |
Nausea |
6 |
Heart Dysfunction |
5 |
Fatigue |
5 |
Vomiting |
5 |
Edema |
4 |
Acute kidney injury |
4 |
Dr. Hu concluded the presentation by stating that the BMCA CAR T treatment is safe and has prominent efficacy. The main obstacle is relapse, and combination therapy could be used to prevent this. Evidence from this study supports the further development of this anti-myeloma immunotherapy.
Yongxian H. et al. High expansion level and long term persistence of BCMA CAR-T cells contribute to potent anti-tumor activity against heavily treated multiple myeloma patients. 2019 Mar 27. Oral Session 20-3: European Society for Blood and Marrow Transplantation, Frankfurt, Germany.
Your opinion matters
IMW 2019 | Overview of novel cellular therapies in MM
Overview of novel cellular therapies in MM
IMW 2019 | Overview of novel cellular therapies in MM
Overview of novel cellular therapies in MM
Subscribe to get the best content related to multiple myeloma delivered to your inbox